Bert Vogelstein

Affiliations:

Johns Hopkins University School of Medicine, Baltimore, MD, United States

Area:

Cancer

Website:

http://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/vogelstein.html

Google:

"Bert Vogelstein"

Bio:

Demonstrated that p53 was a tumor-suppressor gene.

Mean distance: 39813

Tree Publications Similar researchers PubMed Report error

Parents

Howard Dintzis

research assistant

MIT

Children

Luis F. Costa	grad student	2000	Johns Hopkins
Daniel Cahill	grad student	2001	Johns Hopkins (Neurotree)
Meredith Safford	grad student	2001	Johns Hopkins
Jian Yu	grad student	2001	Johns Hopkins
Timothy A. Chan	grad student	2002	Johns Hopkins (DevTree)
C. Giovanni Traverso	grad student	1998-2003	Johns Hopkins
Jordan M. Cummins	grad student	2006	Johns Hopkins
Ian S. Cheong	grad student	2007	Johns Hopkins
Carlo Rago	grad student	2009	Johns Hopkins
Dong Shen	grad student	2009	Johns Hopkins
Jihye Yun	grad student	2009	Johns Hopkins
Jimmy Cheng-Ho Lin	grad student	2011	Johns Hopkins
William P. Hendricks	grad student	2012	Johns Hopkins
Nicholas J. Roberts	grad student	2012	Johns Hopkins
Nicholas J. Roberts	grad student	2012	Johns Hopkins
Andrew Feinberg	post-doc
Sandra B. Gabelli	post-doc		Johns Hopkins Medical School/HHMI
Drew M. Pardoll	post-doc		Johns Hopkins Medical School (Cell Biology Tree)
Ben Ho Park	post-doc		Johns Hopkins Medical School (GenetiTree)
Tian-Li Wang	post-doc	2001-2003	HHMI (Cell Biology Tree)
Surojit Sur	post-doc	2001-2007	Johns Hopkins Medical School
Sergio Rey	post-doc	2011-2013	(Cell Biology Tree)

Collaborators

Sandra B. Gabelli	collaborator		Johns Hopkins Medical School/HHMI
Sambit Panda	collaborator	2023-	(Neurotree)

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Cook AL, Sur S, Dobbyn L, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. Elife. 13
Mog BJ, Marcou N, DiNapoli SR, et al. (2024) Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities. Science Translational Medicine. 16: eadg7123
Nichakawade TD, Ge J, Mog BJ, et al. (2024) TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature
Douville C, Lahouel K, Kuo A, et al. (2024) Machine learning to detect the SINEs of cancer. Science Translational Medicine. 16: eadi3883
Cook AL, Sur S, Dobbyn L, et al. (2023) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. Biorxiv : the Preprint Server For Biology
Chan TA, Hermeking H, Lengauer C, et al. (2023) Author Correction: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature
Wright KM, DiNapoli SR, Miller MS, et al. (2023) Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. Nature Communications. 14: 5063
Rincon-Torroella J, Molin MD, Mog B, et al. (2023) ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. Biorxiv : the Preprint Server For Biology
Lu S, Mattox AK, Aitana Azurmendi P, et al. (2023) The rapid and highly parallel identification of antibodies with defined biological activities by SLISY. Nature Communications. 14: 17
Cook AL, Wyhs N, Sur S, et al. (2022) An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. Iscience. 25: 104437